OCWP
TGTX icon

Owl Creek Wealth Partners’s TG Therapeutics TGTX Stock Holding History

Owl Creek Wealth Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65K Hold
30
– – ﹤0.01% 1170
2026
Q1 		$997 Buy
+30
New +$894 ﹤0.01% 1159

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Owl Creek Wealth Partners's TGTX Position: Q2 2026 in Review

Owl Creek Wealth Partners held its TG Therapeutics (TGTX) position steady in Q2 2026 at 30 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #1170.

Owl Creek Wealth Partners first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Owl Creek Wealth Partners held 30 shares of TG Therapeutics worth $1.65K as of Q2 2026.
  • Owl Creek Wealth Partners left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1170 holding.
  • Owl Creek Wealth Partners first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.